- Asahi Kasei completed acquisition of Aicuris and will advance the portfolio via its U.S. subsidiary Veloxis Pharmaceuticals.
- Aicuris contributes three antiviral assets: Prevymis royalties, pritelivir (FDA Priority Review; PDUFA Q4 2026) and AIC468 (Phase I completed).
- Prevymis royalties are projected at $100–200M annually and Aicuris revenue is expected to reach $500M by 2030 (excluding AIC468).
- Pritelivir targets ~15,000 immunocompromised U.S. patients with potential ~70% second-line penetration and peak sales >$400M in the mid–late 2030s; AIC468 addresses BK virus with a >$1B market opportunity.
Acquisition
Asahi Kasei completed the acquisition of Aicuris, adding antiviral assets to expand its specialty pharmaceutical focus on severe infectious diseases and transplant-related infections.
Assets and regulatory status
Aicuris contributes three antiviral assets: Prevymis (royalty stream), pritelivir (FDA Priority Review; PDUFA Q4 2026) and AIC468 (Phase I complete, developed for BK virus in kidney and hematopoietic stem cell transplant recipients).
Financial and market projections
Prevymis royalties are projected at $100–200M annually and Aicuris revenue is expected to reach $500M by 2030 excluding AIC468; pritelivir targets ~15,000 immunocompromised U.S. patients with potential ~70% second-line penetration and peak sales above $400M in the mid–late 2030s, while AIC468 targets a BK virus market estimated at over $1B.
Integration and timing
Asahi Kasei will advance the portfolio through its U.S. subsidiary Veloxis Pharmaceuticals, leveraging transplant-focused R&D and commercial capabilities; the acquisition is expected to contribute positively to operating income after amortization from fiscal 2028 onward.
